Investor

Invivo Partners

invivo.partners ↗ ·Barcelona ·Early stage ·Actively investing

Invivo Partners is a Barcelona-based venture capital firm founded in 2012 by Luis Pareras and Albert Ferrer, investing in early-stage biotechnology and AI/deeptech companies at the intersection of health, therapeutics, and technology. They back European (especially Spanish) companies from pre-seed/seed through Series A, with initial checks of €2-4M and follow-ons up to €10M. The firm is preparing to deploy a new €100M fund, Invivo Ventures III, and holds a portfolio of around 17 companies.

Portfolio
8
Team
14
AUM
~€150M
Rounds
11
Cheque
€2–4M
SectorsBiotechnology, Advanced therapies, Synthetic biology, Deep tech, AI-driven healthcare VC MapSeed

Profile updated 17 Jul 2026

Team

Partners 6 Investment Team 6 Others 2
Albert Ferrer
Founder & Partner
Claudio Santos
Venture Partner
Josep M. (Pep) Martorell
Partner
Laura Rodríguez
Partner
Luis Pareras
Founder & Managing Partner
Michael Tadros
Venture Partner
Andrés González
Investment Analyst Intern
—
Anna Sampietro
Investment Analyst Intern
Borja Ruiz
Associate
Cinta Díez
Associate
Gemma Guinart
Principal
Marcos Casado
Senior Associate
Begoña Aguirre
Executive Assistant
Oscar Ferrer
Head of Operations and Control

Portfolio companies 8

ARTHEx Biotech
arthexbiotech.com
Company Series B Valencia
Eclova Therapeutics
eclovatx.com
Company Barcelona
Gyala Therapeutics
gyalatx.com
Company Seed Barcelona
Integra Therapeutics
integra-tx.com
Company Other Barcelona
OneChain Immunotherapeutics
onechaintx.com
Company Seed Barcelona
Pulmobiotics
pulmobio.com
Company Seed Barcelona
Telomere Therapeutics
telomere-tx.com
Company Seed Madrid
Telum Therapeutics
telumtherapeutics.com
Company Series A Noáin

Funding rounds 11

Telum Therapeutics · Series A · €18M
Endolysin-antimicrobials biotech secured an €18M Series A co-led by the AMR Action Fund and Inveready to take its lead candidate against dru…
2026-06-30
ARTHEx Biotech · Series B · $87M
ARTHEx Biotech announced it had upsized its Series B to $87M total with new investor Bpifrance (via its Large Venture and InnoBio funds) lea…
2025-09-17
Gyala Therapeutics · Seed · €3M
Gyala Therapeutics, a spin-off of Hospital Clínic de Barcelona and IDIBAPS, raised €3M from Invivo Partners, Nara Capital and CDTI Innvierte…
2025-09-16
Integra Therapeutics · Seed · €10.7M
Integra Therapeutics, a Pompeu Fabra University spin-off developing the FiCAT gene-writing platform, closed a €10.7 million pre-Series A rou…
2025-09-08
Gyala Therapeutics · Series A
CDTI Innovación announced, via its Innvierte programme, that it is entering the capital of Gyala Therapeutics alongside NARA Health Capital …
2024-10-15
OneChain Immunotherapeutics · Seed · €6.7M
Barcelona CAR-T cell therapy developer OneChain Immunotherapeutics, a 2020 spin-off of the Josep Carreras Leukaemia Research Institute, clos…
2023-06-22
ARTHEx Biotech · Series B · €42M
Valencia-based clinical-stage biotech ARTHEx closed a €42M Series B led by Columbus Venture Partners to take ATX-01, an antimiR targeting mi…
2023-05-03
Telomere Therapeutics · Seed · €1.5M
Telomere Therapeutics is a spin-off of CNIO and UAB, founded by Maria Blasco and Fàtima Bosch. It is developing a telomerase gene therapy fo…
2020-12-01
Arthex Biotech · Series A · €4.25M
Arthex is a preclinical biotech developing antisense RNA therapies for myotonic dystrophy type 1. Invivo Ventures and Advent France Biotechn…
2020-07-23
Telum Therapeutics · Seed · €4.1M
Telum Therapeutics raised €4.1M in its first round to develop enzybiotics, which are therapies based on bacteriophage lytic enzymes, against…
2020-07-13
Gyala Therapeutics · Seed · €1.5M
Gyala Therapeutics, a spin-off of Hospital Clínic-IDIBAPS developing new CAR-T therapies for blood cancers, raised €1.5M in seed financing f…
2020-05-26

News & media 7

PublishedArticle
2026-08-03 Julio consolida un verano récord en inversión: 672,85M€ en 38 operaciones ↗
El Referente
2025-10-02 Invivo Partners Prepares the Launch of a €100M Fund at the Intersection of AI and Science and Welcomes Pep Martorell as Partner ↗
AI Insider
2025-03-17 AstraZeneca adds 'in vivo' cell therapy capabilities with EsoBiotec deal ↗
BioPharma Dive
2025-01-18 Biotech: Angelini Ventures Leads €20 Million Financing Round for Neumirna Therapeutics: Pioneering RNA-Based Therapies for Neurological Disorders ↗
ITTBioMed
2024-03-06 European VC Invivo readies its latest fund to back new biotechs ↗
BioPharma Dive
2023-12-12 Invivo Ventures Invests in EsoBiotec to Revolutionize Cancer Cell Therapy with Cutting-Edge In Vivo Engineering Platform ↗
Invivo Partners
2023-09-07 Corteria Pharmaceuticals Raises €65M in Series A Funding ↗
FinSmes
Start typing to search across everything.
↑↓ navigate↵ openesc close